With the continuous advancement of science and technology, brain-computer interface (BCI) technology is gradually moving from theory to practice, and Inbrain Neuroelectronics is a pioneer in this field. The company's graphene chip brain-computer interface technology is about to enter a new milestone - the human brain measurement stage. The company plans to test its graphene-based brain-computer interface this summer during surgery to remove brain tumors for patients at the University of Manchester in the United Kingdom. The application of this technology not only has revolutionary potential in the medical field, but also provides a new direction for the future development of brain-computer interface technology.
Graphene: The Miracle of Materials Science
Graphene, a two-dimensional material formed by a single layer of carbon atoms arranged in a honeycomb pattern, is known for its excellent electrical conductivity, thermal conductivity, and mechanical strength. Inbrain Neuroelectronics has developed a new type of brain-computer interface by using these properties of graphene. Compared to traditional metal electrodes, graphene chips are not prone to Faraday reactions and can work stably at voltages up to 200 times without initiating any electrochemical oxidation process.
Preclinical Studies: Verification of Safety and Efficacy
Inbrain Neuroelectronics has been conducting three years of preclinical studies to verify the biocompatibility and safety of graphene brain-computer interfaces in large animal models before entering human brain testing. These studies not only demonstrated the compatibility of graphene chips with biological tissues, but also demonstrated their potential in reducing Parkinson's symptoms. According to IEEE Spectrum, Inbrain's chief executive officer Carolina Aguilar said the company's technology has shown superiority over current commercial technologies in preclinical studies.
Figure: Graphene chip brain-computer interface technology will enter the stage of human brain measurement (schematic diagram).
Human Brain Measurement: The Leap from Theory to Practice
This summer, Inbrain Neuroelectronics plans to conduct the first human brain test at the University of Manchester in the United KingdomC, which will be an important moment in the history of graphene brain-computer interface technology. In this test, the graphene brain-computer interface will be used to assist in brain tumor resection surgery, which will not only verify its feasibility in practical medical operations, but also provide valuable data and experience for future clinical applications.
Future applications: hope for the treatment of epilepsy and Parkinson's disease
Inbrain Neuroelectronics' graphene brain-computer interface technology not only has the potential to be used in brain tumor removal surgery, but the company also plans to apply it to the treatment of epilepsy and Parkinson's disease. According to the company's official website, its platform has received breakthrough device designation from the FDA for the treatment of Parkinson's disease. This certification is not only a recognition of Inbrain's technology, but also opens the way for the application of graphene brain-computer interface in the field of neurological disease treatment.
All in all, Inbrain Neuroelectronics' graphene chip brain-computer interface technology is about to enter the human brain testing stage, which marks an important advance in BCI technology. From innovations in materials science to the exploration of clinical applications, Inbrain Neuroelectronics is at the forefront of the development of brain-computer interface technology. With the continuous maturity of technology and the deepening of clinical trials, we have reason to believe that graphene brain-computer interface will bring revolutionary changes to the treatment of neurological diseases and bring new hope to patients.
